LIFE AI Announcement

Why is validation so difficult to accelerate? Because unlike discovery, validation cannot be completed in isolation. An AI-generated drug candidate still has to move through key players across the healthcare value chain, including pharma teams, clinical sites, hospitals, clinicians, patients, and regulators. Each operates with different timelines, evidence requirements, compliance constraints, and operational priorities. A candidate can move forward on one front while remaining constrained elsewhere, whether by patient recruitment, study execution, evidence generation, or the decisions required to advance it. This makes validation more operationally complex than discovery. Discovery can be accelerated within a model, platform, or controlled environment, while validation depends on how effectively these key players coordinate and execute across the development process. With more candidates entering development, that operational complexity compounds, requiring more evidence generation, clinical execution, patient participation, and coordinated decision making across organizations. As AI accelerates discovery, the need for better coordination and the infrastructure to support it becomes increasingly important downstream.

AI is accelerating drug discovery. But the pressure is shifting downstream, toward the work required to validate what discovery produces. Across science and life sciences, AI is moving deeper into discovery. Anthropic is expanding AI into scientific research, Isomorphic Labs is scaling AI-first drug design and development, and Discovery Loop is building systems to automate experimental loops. As these capabilities advance, more targets can be explored, more molecules can be designed, and more potential candidates can be generated. The discovery layer is becoming faster and more expansive. But accelerating discovery does not automatically accelerate the path to validation. A promising candidate still has to be evaluated, tested, and supported by sufficient evidence before it can move forward. Clinical validation is where this downstream pressure becomes especially visible. The gains from faster discovery can begin to narrow if the path to validation remains slow and difficult to scale. For Life AI, this raises a critical question: How do we make sure the path to validation can keep pace as AI accelerates discovery?

AI is moving faster than the systems around it. In healthcare, that gap matters. But what makes that gap so difficult to close? “How do we turn AI intelligence into accountable action across fragmented healthcare systems?” It is also a question that has increasingly shaped how Life AI thinks about healthcare AI. Speaking at NVIDIA GTC Taiwan 2026, Life AI Co-Founder and CEO Dr. Tuan Cao put it this way:

“In other industries, if you have the best model, you win. But in healthcare, what actually matters is the coordination of so many key players across the healthcare value chain. That is why running a clinical trial in the US is so expensive. It costs about $20 million to $100 million to run a Phase III clinical trial, and for every patient, we pay about $500,000 because the man in the middle has to coordinate so many different players: the pharma, the hospital, the patient, and the doctor. So coordination of all of those key players is actually one of the main bottlenecks.”

The challenge is not simply advancing AI, but understanding what it takes to make AI work across the complexity of healthcare. The NVIDIA Inception Grand Challenge 2026 gives Life AI a timely platform to bring this infrastructure question into a broader AI conversation.

Life AI Named a Top 20 Finalist in the NVIDIA Inception Grand Challenge 2026 Life AI has been named one of the Top 20 Finalists in the NVIDIA Inception Grand Challenge 2026, selected from more than 500 startups across Asia Pacific. The recognition follows Life AI’s selection in 2025 as one of six startups in the inaugural FastTrack AI Accelerator, powered by GenAI Fund and accelerated by the NVIDIA Inception Program. On September 22, our co-founder and CEO, Dr. Tuan Cao, will present Life AI’s perspective at the Grand Challenge Finale during NVIDIA AI Day Singapore. But the significance of this milestone extends beyond the competition. AI capabilities are advancing at unprecedented speed. Yet in healthcare, building more capable AI is only the beginning. The harder challenge is making that intelligence usable inside systems that were never designed to work together. Clinical records, workflows, validation processes, and decision-making remain distributed across hospitals, laboratories, pharmaceutical companies, and care teams. Moving AI from isolated pilots into real-world practice therefore requires more than a powerful model. It requires a way to connect signals, coordinate actions, and maintain accountability across those boundaries. As AI intelligence becomes increasingly abundant, how do we turn it into accountable action across fragmented healthcare systems? That is the question Life AI is taking to Singapore. In the weeks ahead, we will share how we are approaching it.

The next edge in drug development will come from understanding patients at higher resolution. For decades, clinical evidence was shaped by scheduled visits. What patients reported. What clinicians observed. Everything between visits remained largely unseen. The FDA’s Digital Health Technologies program is expanding the use of continuous and frequent measurements beyond traditional study visits, including through wearables, sensors, and remote monitoring. For drug development, this opens the possibility of following treatment response beyond scheduled assessments and across the patient journey. But capturing these signals is only part of the challenge. Biological signals, interventions, and outcomes remain fragmented across the patient journey. Without coordination, the longitudinal picture remains incomplete. The next infrastructure layer will need to connect these signals with interventions and outcomes across time, institutions, and real-world conditions. As the FDA advances the regulatory pathway for digitally derived endpoints, that coordination layer becomes increasingly important to drug development. Source: FDA, Digital Health Technologies for Drug Development

AI can now generate more drug and treatment candidates than the healthcare industry can ever validate. That gap between what AI can discover and what actually reaches patients is the problem Life AI was built to close. What we're most excited about in the Google for Startups Accelerator: Southeast Asia program is the chance to work directly with Google's engineering teams on scaling that infrastructure, the rails that help hospitals and pharma partners move healthcare AI programs from pilot to real, deployed care. We've already seen what's possible when this works: programs that used to take years now take months, at a fraction of the cost, while still meeting regulatory standards. Over the next three months, we'll be pressure testing our technology alongside some of the best AI minds in the industry, building toward a technical residency in San Francisco. More soon. #AcceleratedWithGoogle

AI in drug development is entering a more demanding phase. As candidates move through the development pipeline, they face increasingly complex challenges across biological validation, translational risk, patient heterogeneity, and the timing of evidence. Many candidates enter the pipeline. Far fewer progress toward clinical validation. The next frontier is not simply increasing the number of candidates. It is generating robust, validated, decision ready evidence earlier in the development process, enabling more informed decisions at critical stages.

Exciting news! Life AI have been selected for the Google for Startups Accelerator: Southeast Asia program! Follow us as we dive into this incredible opportunity and showcase our journey through innovative AI solutions. [goo.gle/4wIlbsP] #AcceleratedWithGoogle

AI in drug development is moving beyond isolated use cases and becoming a portfolio of decision support capabilities across the full development lifecycle. In discovery, AI supports target identification, molecule design, screening, and lead optimization. In nonclinical development, AI supports toxicity assessment, pharmacology modeling, and translational risk analysis. In clinical development, AI supports patient stratification, trial feasibility, endpoint selection, dose optimization, and safety monitoring. In postmarketing, AI supports real world data analytics, signal detection, subgroup analysis, and long term treatment performance. In manufacturing, AI supports process monitoring, quality control, and production consistency. The strategic opportunity is not to apply AI more broadly for its own sake. It is to apply AI where uncertainty is highest and decisions are most consequential, where better evidence earlier can improve validation, reduce development risk, and strengthen the basis for advancing the right therapies toward patients. That is the standard by which AI in drug development will increasingly be measured.

AI is becoming an increasingly integrated part of drug development. The FDA’s Center for Drug Evaluation and Research (CDER) has observed growing use of AI across the drug product lifecycle, including nonclinical, clinical, manufacturing, and postmarketing activities. The scale is already significant. Between 2016 and 2023, CDER gained experience with more than 500 submissions containing AI components. This experience helped inform the FDA’s 2025 draft guidance on the use of AI to support regulatory decision making. For pharma and biotech, this signals a broader shift. AI-enabled drug development is moving beyond individual discovery applications. It is increasingly being applied to the information and data that support development and regulatory decisions. That also raises the requirements for how these systems are developed and evaluated. Key considerations include context of use, risk-based validation, data governance, performance assessment, documentation, and lifecycle management. The next phase of AI in drug development will be measured by more than speed. It will be measured by the credibility, traceability, and confidence of the evidence AI helps generate for development and regulatory decisions. Sources: FDA — Artificial Intelligence for Drug Development: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development FDA — Considerations for the Use of AI to Support Regulatory Decision-Making: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological

Identifying a health risk early and acting without delay can be life-changing. Earlier intervention depends on: - reading biological signals before symptoms surface - monitoring risk markers continuously, not episodically - infrastructure that translates early intelligence into timely action The science exists. The signals are there. What changes outcomes is whether the system is close enough to act on them in time.

Brain health is shaped long before memory loss begins. A study published in Neurology followed more than 12,000 adults over 26 years and found a clear link between midlife vascular risk and years lived without dementia. Three risk factors stood out: High blood pressure → Diabetes → Smoking People without these risk factors lived significantly more years without dementia than those with all three. This highlights a critical window for prevention: midlife. Dementia risk can accumulate over decades through vascular, metabolic, behavioral, and lifestyle patterns, long before cognitive decline becomes apparent. For healthcare, this shifts the focus toward understanding how risk evolves over time and identifying opportunities for intervention earlier. The goal is to recognize changing risk trajectories, support timely action, and protect brain health before symptoms emerge. Better brain health starts with earlier health intelligence. Source: Neurology — “Midlife Vascular Risk Burden and Dementia-Free Survival Years” https://www.neurology.org/doi/10.1212/WN9.0000000000000152

A healthcare AI program requires more than a model. Translating a concept into clinical deployment demands specialized expertise across the full development lifecycle: → Domain experts to define the clinical problem → Clinical investigators to establish validity and safety → Clinical integrators to operationalize within clinical environments Each discipline is non-substitutable. Each becomes harder to coordinate as program volume scales. This is the structural constraint computational advancement alone cannot resolve. Computational capacity scales exponentially. Clinical expertise accumulates incrementally. The solution is not to reduce the role of expertise. It is infrastructure that makes specialized expertise composable, reused across programs, not reconstructed for each one.

Earlier detection is only useful if healthcare can act on the signal. Chronic disease develops over time, leaving measurable signals across biomarkers, clinical history, behavior, and longitudinal health data. AI can analyze these signals at scale, identify emerging patterns, and surface potential risks earlier. But detection is only one layer of the healthcare workflow. An identified risk still needs to move through: Detection → Clinical Assessment → Evidence → Intervention → Monitoring Each stage introduces different requirements for clinical expertise, evidence, workflow integration, and continuous feedback. This is where the next challenge for Healthcare AI emerges. AI can increase the speed and scale of detection. The healthcare system must be able to process what that detection produces. The objective is not simply to identify risk earlier. It is to establish a continuous pathway from: Signal → Evidence → Decision → Intervention → Outcome That is what turns AI assisted detection into measurable clinical impact.

Delivering effective preventive health requires collaboration between: — individuals tracking their own health signals, — clinicians acting on earlier information, — researchers learning from real-world outcomes, and — health systems building the infrastructure that connects them. Together, we can build care that reaches people before they need it.

Diabetes often becomes visible to healthcare after the metabolic pattern has been building for years. The OECD estimates that tens of millions of adults across member countries are living with undiagnosed diabetes. Not because the signals are missing, but because healthcare is still designed to detect disease in episodes, while metabolic change happens continuously. Diabetes is more than a blood sugar disorder. It is the accumulation of metabolic drift: gradual changes in glucose, weight, sleep, activity, diet, medication adherence, and related conditions that compound long before a diagnosis is made. By the time diabetes is clinically visible, the trajectory has often been unfolding for years. The future of diabetes prevention is not simply earlier diagnosis. It is recognizing metabolic drift while it is still reversible.

Healthcare is moving beyond one size fits all prevention. The next generation of prevention is built on context. General recommendations still matter. But prevention becomes far more effective when it understands why risk is different for every individual. That requires connecting signals across: • Biomarkers • Behavior • Environment • Medical history • Longitudinal outcomes The value is not in collecting more data. It is in understanding how those signals interact over time. When healthcare systems can identify changing risk earlier and evaluate which interventions actually work, prevention becomes proactive instead of reactive. That is the direction personalized healthcare is heading.

As healthcare AI moves closer to clinical decision making, the focus is expanding beyond model performance. The quality of a recommendation also depends on the quality, completeness, and provenance of the data behind it. Duplicated records, outdated observations, or incomplete patient histories can all influence how a recommendation is generated and how it should be interpreted. This places greater emphasis on making the underlying evidence visible, not just the final output. That includes understanding: • Where the data came from • How recent it is • What information may be missing • Which clinical evidence supports the recommendation • Where uncertainty remains These signals provide important context for interpreting AI generated recommendations within clinical workflows. As healthcare AI becomes more integrated into care delivery, making evidence easier to understand is becoming just as important as improving model performance.

Did you know? Up to 80% of premature heart disease, stroke, and type 2 diabetes cases are preventable through lifestyle changes. Most people don’t find out until it’s too late. You can change that: - Know your numbers: blood pressure, glucose, cholesterol - Move regularly, even in small amounts - Eat in ways that support your biology - Protect your sleep, it affects everything - Track changes over time, not just at annual checkups Prevention works. It just needs to start earlier.

More than 57 million people worldwide are living with dementia. The latest WHO guidelines estimate that up to 45% of dementia risk could be prevented or delayed by addressing modifiable risk factors across the life course. That changes how we should think about brain health. Dementia develops over decades through measurable signals including blood pressure, metabolic health, physical activity, hearing, smoking, alcohol use, and social connection. The greatest impact comes from identifying these signals early and building the infrastructure to help people protect their brain health before cognitive decline begins. Brain health starts long before diagnosis. Source: World Health Organization. New WHO guidelines: up to 45% of dementia risk could be prevented or delayed (15 July 2026). https://www.who.int/news/item/15-07-2026-new-who-guidelines--up-to-45--of-dementia-risk-could-be-prevented-or-delayed